CN115515603A - 用于治疗戊型肝炎的双环和单环核苷类似物 - Google Patents

用于治疗戊型肝炎的双环和单环核苷类似物 Download PDF

Info

Publication number
CN115515603A
CN115515603A CN202180028212.9A CN202180028212A CN115515603A CN 115515603 A CN115515603 A CN 115515603A CN 202180028212 A CN202180028212 A CN 202180028212A CN 115515603 A CN115515603 A CN 115515603A
Authority
CN
China
Prior art keywords
compound
compounds
mmol
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180028212.9A
Other languages
English (en)
Chinese (zh)
Inventor
T·H·M·琼克斯
F·保韦尔斯
Y·德宾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of CN115515603A publication Critical patent/CN115515603A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN202180028212.9A 2020-04-14 2021-04-13 用于治疗戊型肝炎的双环和单环核苷类似物 Pending CN115515603A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20169480 2020-04-14
EP20169480.9 2020-04-14
PCT/EP2021/059504 WO2021209419A1 (en) 2020-04-14 2021-04-13 Bi- and monocyclic nucleoside analogs for treatment of hepatitis e

Publications (1)

Publication Number Publication Date
CN115515603A true CN115515603A (zh) 2022-12-23

Family

ID=70289599

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180028212.9A Pending CN115515603A (zh) 2020-04-14 2021-04-13 用于治疗戊型肝炎的双环和单环核苷类似物

Country Status (15)

Country Link
EP (1) EP4135715B1 (cg-RX-API-DMAC7.html)
JP (2) JP2023522615A (cg-RX-API-DMAC7.html)
KR (1) KR20230002592A (cg-RX-API-DMAC7.html)
CN (1) CN115515603A (cg-RX-API-DMAC7.html)
AR (1) AR121836A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021255809B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022020825A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174790A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002804A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982564T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022012904A (cg-RX-API-DMAC7.html)
PE (1) PE20230386A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552679A1 (cg-RX-API-DMAC7.html)
UY (1) UY39172A (cg-RX-API-DMAC7.html)
WO (1) WO2021209419A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024086592A2 (en) * 2022-10-17 2024-04-25 Emory Unversity 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2025014360A1 (en) * 2023-07-07 2025-01-16 Erasmus University Medical Center Rotterdam Guanosine nucleotide analogs for use in preventing and/or treating hepatitis e virus infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150011497A1 (en) * 2013-06-26 2015-01-08 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US20150366888A1 (en) * 2014-06-24 2015-12-24 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN106604734A (zh) * 2014-06-24 2017-04-26 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017210438A1 (en) * 2016-06-03 2017-12-07 Gilead Pharmasset Llc Methods of treating hepatitis e viral infection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150011497A1 (en) * 2013-06-26 2015-01-08 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US20150366888A1 (en) * 2014-06-24 2015-12-24 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN106573011A (zh) * 2014-06-24 2017-04-19 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物
CN106604734A (zh) * 2014-06-24 2017-04-26 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物

Also Published As

Publication number Publication date
CA3174790A1 (en) 2021-10-21
US20230310481A1 (en) 2023-10-05
EP4135715A1 (en) 2023-02-22
CL2022002804A1 (es) 2023-03-31
AU2021255809B2 (en) 2026-08-06
PH12022552679A1 (en) 2024-04-22
BR112022020825A2 (pt) 2022-11-29
EP4135715B1 (en) 2024-05-08
ES2982564T3 (es) 2024-10-16
MX2022012904A (es) 2023-01-24
AU2021255809A1 (en) 2022-12-15
PE20230386A1 (es) 2023-03-06
UY39172A (es) 2021-10-29
EP4135715C0 (en) 2024-05-08
WO2021209419A1 (en) 2021-10-21
AR121836A1 (es) 2022-07-13
KR20230002592A (ko) 2023-01-05
JP2023522615A (ja) 2023-05-31
JP2026120528A (ja) 2026-07-22

Similar Documents

Publication Publication Date Title
JP6742403B2 (ja) アレナウイルス科およびコロナウイルス科のウイルス感染を処置するための方法
KR102453808B1 (ko) 필로비리다에 바이러스 감염을 치료하는 방법
CN102348713B (zh) 用于抗病毒治疗的carba-核苷类似物
CN103052637B (zh) 醛糖还原酶抑制剂及其用途
KR20140019832A (ko) 항바이러스 치료를 위한 1''-치환 피리미딘 ν-뉴클레오사이드 유사체
BR112015020472B1 (pt) composto de fosforamidato de nucleosídeo, composição farmacêutica e uso do mesmo
JP5777696B2 (ja) 2’,2−ビスチアゾール非ヌクレオシド系化合物及びその調製方法、医薬組成物、及び抗肝炎ウイルス阻害剤としての用途
EP4135715B1 (en) Bi- and monocyclic nucleoside analogs for treatment of hepatitis e
HK40085931A (en) Bi- and monocyclic nucleoside analogs for treatment of hepatitis e
OA21046A (en) BI- and monocyclic nucleoside analogs for treatment of hepatitis E.
CN115443138A (zh) 用于治疗戊型肝炎的螺环核苷类似物
HK40088561A (en) Bi- and monocyclic nucleoside analogs for treatment of hepatitis e
HK40088561B (en) Bi- and monocyclic nucleoside analogs for treatment of hepatitis e
CN118005694B (zh) 一种环状核苷类似物及其制备方法和应用
JP2023521425A (ja) E型肝炎の治療のためのアルキニルヌクレオシド類似体
HK40090491A (en) Alkynyl nucleoside analogs for treatment of hepatitis e
HK40085110A (en) Spirocyclic nucleoside analogues for the treatment of hepatitis e
CN118978524A (zh) 硝唑尼特衍生物及其医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40085931

Country of ref document: HK